Lupin partners with Spanish pharma company for launch of Luforbec inhalers in Spain; check stock performance

Drugmaker Lupin on Monday, June 8, announced a strategic collaboration with the Spanish pharmaceutical company, Laboratorios ERN S.A., for the launch of the Luforbec inhaler in Spain.

Luforbec (beclometasone/formoterol) 100/6, which will be launched in Spain, is a fixed-dose combination in a pressurised metered-dose inhaler used for treating adults with asthma and chronic obstructive pulmonary disease, according to a regulatory filing.

This collaboration combines Lupin’s global respiratory expertise and proven pMDI manufacturing excellence and ERN’s robust national reach and deep customer relationships, marking an exciting milestone in expanding high-quality respiratory care to patients across Spain, the filing said.

Commenting on the development, Thierry Volle, President EMEA and Emerging Markets, Lupin, said: “The launch of Luforbec in Spain, following successful introductions in the UK and Germany, represents a key milestone in our partnership with ERN and reinforces our commitment to advancing global access to quality respiratory care. Together, we are building something truly exciting for patients and healthcare professionals.”

Laboratorios ERN S.A. is a Spanish pharmaceutical company with headquarters in Barcelona. The company currently manufactures more than 28 million units per year and commercialises a portfolio of over 35 active pharmaceutical ingredients in Spain.

“Partnering with Lupin allows us to bring a proven, high‑value respiratory therapy to Spanish patients and healthcare professionals. It represents an opportunity for ERN to expand into a new therapeutic area,” said David Solanes, CEO of Laboratorios ERN S.A.

Lupin stock performance

Shares of Lupin were trading flat with a negative bias at around 1:56 PM on the National Stock Exchange (NSE).

Lupin’s shares had recovered to trade in the green zone following the announcement, before falling back into the negative territory.

The share has fallen 5% over the month but gained 8% on a year-to-date basis.

While the stock hit a 52-week high of ₹2,494 per equity share on May 7, 2026, it touched a year’s low of ₹1,836.80 per unit on August 6, 2025.

Lupin has a total market capitalisation of ₹1.04 lakh crore as of June 8, 2026, according to data on the NSE.